12:00 AM
 | 
Dec 19, 2005
 |  BioCentury  |  Finance

Walking past the competition

Walking past the competition

Walking past the competition
Investors put a lot on chips on Myogen's ambrisentan last week, even though it would be the third endothelin receptor antagonist on the market for pulmonary arterial hypertension. Data from the first of two Phase III trials of ambrisentan showed that...

Read the full 248 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >